Baker Bros. Advisors LP Travere Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$18.47 - $26.14 $38.3 Million - $54.2 Million	-2,074,754 Reduced 62.87%	1,225,255 $25.8 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $14.9 Million - $19.3 Million	630,955 Added 23.64%	3,300,009 $85 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $15.3 Million - $19.6 Million	629,282 Added 30.85%	2,669,054 $82.8 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $24.1 Million - $46.4 Million	1,852,857 Added 991.28%	2,039,772 $49.5 Million
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $4.37 Million - $5.94 Million	186,915 New	186,915 $4.67 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.